Mediar raises $105 million to target fibrotic mediators

16 March 2023
mediar_therapeutics_large

Fibrosis-focused Mediar Therapeutics has added $105 million to its coffers.

The US firm’s fundraising includes an $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol Myers Squibb (NYSE: BMY), Eli Lilly (NYSE: LLY), Ono Venture Investment and Mass General Brigham Ventures.

The latter company co-founded Mediar alongside Mass General and Brigham and Women’s Hospitals with the goal to transform the treatment of fibrotic disease by targeting the myofibroblast, the key cell type driving fibrosis progression.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology